SCHEMBL5373048

SCHEMBL5373048

Cc1cccc(C2(O)CCN(C(=O)O)CC2)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 5/20 0.60
OPRK1 P41145 5/20 0.60
OPRL1 P41146 5/20 0.60
OPRD1 P41143 4/20 0.60
CYP46A1 Q9Y6A2 1/20 0.49
ALDH1A1 P00352 3/20 0.49
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
SOS1 Q07889 1/20 0.45
HDAC4 P56524 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.43
LMNA P02545 1/20 0.43
GABRD O14764 1/20 0.43
GABRA1 P14867 1/20 0.43
GABRB1 P18505 1/20 0.43
GABRA5 P31644 1/20 0.43
GABRA3 P34903 1/20 0.43
GABRA2 P47869 1/20 0.43
GABRB2 P47870 1/20 0.43
GABRA4 P48169 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22055641 0.88 OPRM1 (0.57) OPRM1OPRK1OPRL1OPRD1CYP46A1
SCHEMBL5368030 0.84 CYP46A1 (0.41) OPRM1OPRK1OPRL1OPRD1CYP46A1
SCHEMBL4812915 0.83 ALDH1A1 (0.55) OPRM1OPRK1OPRL1OPRD1CYP46A1
SCHEMBL795975 0.82 ALDH1A1 (0.56) OPRM1OPRK1OPRL1OPRD1ALDH1A1
SCHEMBL2931056 0.82 OPRM1 (0.52) OPRM1OPRK1OPRL1OPRD1ALDH1A1
SCHEMBL3441859 0.82 OPRM1 (0.60) OPRM1OPRK1OPRL1OPRD1ALDH1A1
SCHEMBL19280276 0.82 ALDH1A1 (0.46) OPRM1OPRK1OPRL1OPRD1ALDH1A1
SCHEMBL2588266 0.81 ALDH1A1 (0.73) OPRM1OPRK1OPRL1OPRD1ALDH1A1
SCHEMBL5368267 0.81 ALDH1A1 (0.47) OPRM1OPRK1OPRL1OPRD1ALDH1A1
SCHEMBL5376329 0.81 ALDH1A1 (0.46) OPRM1OPRK1OPRL1OPRD1CYP46A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1714961-B1 INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2015-12-09 EP claimed
US-20070173537-A1 Indazole compound and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2007-07-26 US claimed
EP-1714961-A1 INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2006-10-25 EP claimed
EP-1714961-B1 INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2015-12-09 EP disclosed
US-20070173537-A1 Indazole compound and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2007-07-26 US disclosed
EP-1714961-A1 INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2006-10-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070173537-A1 Indazole compound and pharmaceutical use thereof CYP3A5, CYP3A43, TP53 OPRM1 3770/4885OPRK1 3177/4885OPRL1 3885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.